3-Acetoxy-8(17),13E-labdadien-15-oic acidCAS# 63399-37-1 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 63399-37-1 | SDF | Download SDF |
| PubChem ID | 13858192 | Appearance | Powder |
| Formula | C22H34O4 | M.Wt | 362.5 |
| Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (E)-5-[(1S,4aR,6S,8aR)-6-acetyloxy-5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-3-methylpent-2-enoic acid | ||
| SMILES | CC(=CC(=O)O)CCC1C(=C)CCC2C1(CCC(C2(C)C)OC(=O)C)C | ||
| Standard InChIKey | OMNJRQNCWHCCBZ-BULWIKRESA-N | ||
| Standard InChI | InChI=1S/C22H34O4/c1-14(13-20(24)25)7-9-17-15(2)8-10-18-21(4,5)19(26-16(3)23)11-12-22(17,18)6/h13,17-19H,2,7-12H2,1,3-6H3,(H,24,25)/b14-13+/t17-,18-,19-,22+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | ent-3-Acetoxy-labda-8(17),13-dien-15-oic acid have vasorelaxant and hypotensive actions, the mechanisms underlying the cardiovascular actions of the labdane involve the activation of the endothelial NO-cGMP pathway, the opening of K+ channels and the alteration on Ca2+ mobilization. |
| Targets | Calcium Channel | cAMP | Potassium Channel | NO |
| In vivo | Mechanisms underlying the vascular and hypotensive actions of the labdane ent-3-acetoxy-labda-8(17),13-dien-15-oic acid.[Pubmed: 24463178 ]Eur J Pharmacol. 2014 Mar 5;726:66-76.We investigated the mechanisms underlying the vasorelaxant and hypotensive actions of the labdane-type diterpene ent-3-acetoxy-labda-8(17),13-dien-15-oic acid (3-Acetoxy-8(17),13E-labdadien-15-oic acid,labda-15-oic acid).
|
3-Acetoxy-8(17),13E-labdadien-15-oic acid Dilution Calculator
3-Acetoxy-8(17),13E-labdadien-15-oic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.7586 mL | 13.7931 mL | 27.5862 mL | 55.1724 mL | 68.9655 mL |
| 5 mM | 0.5517 mL | 2.7586 mL | 5.5172 mL | 11.0345 mL | 13.7931 mL |
| 10 mM | 0.2759 mL | 1.3793 mL | 2.7586 mL | 5.5172 mL | 6.8966 mL |
| 50 mM | 0.0552 mL | 0.2759 mL | 0.5517 mL | 1.1034 mL | 1.3793 mL |
| 100 mM | 0.0276 mL | 0.1379 mL | 0.2759 mL | 0.5517 mL | 0.6897 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- SJB2-043
Catalog No.:BCC1952
CAS No.:63388-44-3
- (+)-Isolariciresinol 9'-O-glucoside
Catalog No.:BCN7014
CAS No.:63358-12-3
- Bromethalin
Catalog No.:BCC5472
CAS No.:63333-35-7
- VU 10010
Catalog No.:BCC7577
CAS No.:633283-39-3
- Secoisolariciresinol monoglucoside
Catalog No.:BCN6990
CAS No.:63320-67-2
- Jacoumaric acid
Catalog No.:BCN3245
CAS No.:63303-42-4
- Azaphen dihydrochloride monohydrate
Catalog No.:BCC1391
CAS No.:63302-99-8
- Berberine hydrogen sulphate
Catalog No.:BCN2574
CAS No.:633-66-9
- Berberine hydrochloride
Catalog No.:BCN6319
CAS No.:633-65-8
- Echiumine
Catalog No.:BCN1972
CAS No.:633-16-9
- Grantianine
Catalog No.:BCN2084
CAS No.:633-10-3
- Calcifediol monohydrate
Catalog No.:BCC1443
CAS No.:63283-36-3
- Alepterolic acid
Catalog No.:BCN4172
CAS No.:63399-38-2
- 8-CPT-2Me-cAMP, sodium salt
Catalog No.:BCC7140
CAS No.:634207-53-7
- Corollin
Catalog No.:BCC8754
CAS No.:63461-31-4
- TBPB
Catalog No.:BCC5517
CAS No.:634616-95-8
- WAY-100635 maleate salt
Catalog No.:BCC2054
CAS No.:634908-75-1
- Lithospermoside
Catalog No.:BCN1270
CAS No.:63492-69-3
- ANR 94
Catalog No.:BCC7815
CAS No.:634924-89-3
- Bilirubin
Catalog No.:BCN1047
CAS No.:635-65-4
- 4,2'-Dihydroxy-4'-methoxychalcone
Catalog No.:BCN7704
CAS No.:63529-06-6
- LY404039
Catalog No.:BCC4592
CAS No.:635318-11-5
- 24,25-Epoxydammar-20(21)-en-3-one
Catalog No.:BCN4173
CAS No.:63543-52-2
- 24,25-Dihydroxydammar-20-en-3-one
Catalog No.:BCN4174
CAS No.:63543-53-3
Mechanisms underlying the vascular and hypotensive actions of the labdane ent-3-acetoxy-labda-8(17),13-dien-15-oic acid.[Pubmed:24463178]
Eur J Pharmacol. 2014 Mar 5;726:66-76.
We investigated the mechanisms underlying the vasorelaxant and hypotensive actions of the labdane-type diterpene ent-3-acetoxy-labda-8(17),13-dien-15-oic acid (labda-15-oic acid). Vascular reactivity experiments were performed in aortic rings isolated from male Wistar rats. cAMP and cGMP were measured by enzyme immunoassay (EIA) whereas nitrate measurement was performed by chemiluminescence. Nitric oxide (NO) concentration ([NO]c) was measured in endothelial cells by flow cytometry. The cytosolic calcium concentration ([Ca2+]c) in vascular smooth muscle cells (VSMC) was measured by confocal microscopy. Blood pressure measurements were performed in conscious rats. Labda-15-oic acid inhibited the contraction induced by phenylephrine and serotonin in either endothelium-intact or endothelium-denuded rat aortic rings. The labdane significantly reduced CaCl2-induced contraction in a Ca2+-free solution containing KCl or phenylephrine. Labda-15-oic acid (0.1-300 mumol/l) concentration-dependently relaxed endothelium-intact and endothelium-denuded aortas pre-contracted with either phenylephrine or KCl. In endothelium-intact rings, the relaxation induced by labda-15-oic acid was affected by L-NAME, 7-nitroindazole, ODQ, hemoglobin, Rp-8-Br-Pet-cGMPS and thapsigargin. Blockade of K+ channels with 4-aminopyridine, apamin, charybdotoxin and glibenclamide affected the relaxation induced by labda-15-oic acid. The labdane increased cGMP and nitrate levels but did not affect cAMP levels in endothelium-intact aortas. Labda-15-oic acid increased [NO]c in endothelial cells and decreased [Ca2+]c in VSMC. The hypotension induced by intravenous administration of labda-15-oic acid (0.3-3 mg/kg) was partially reduced by L-NAME. In conclusion, the mechanisms underlying the cardiovascular actions of the labdane involve the activation of the endothelial NO-cGMP pathway, the opening of K+ channels and the alteration on Ca2+ mobilization.
